SuperworthIovance Biotherapeutics EPS IOVA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.11
- Fiscal year 2024
- −$1.30
Iovance Biotherapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.11.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$1.30 | n/a |
| FY2023 | −$1.88 | n/a |
| FY2022 | −$2.48 | n/a |
| FY2021 | −$2.22 | n/a |
| FY2020 | −$1.89 | n/a |
| FY2019 | −$1.58 | n/a |
| FY2018 | −$1.28 | n/a |
| FY2017 | −$1.41 | n/a |
| FY2016 | −$1.77 | n/a |
| FY2015 | −$0.62 | n/a |
| FY2014 | −$0.49 | n/a |
| FY2013 | −$7.25 | −168% |
| FY2012 | $10.62 | n/a |
| FY2011 | −$34.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.11 | n/a | n/a | |
| Q1 FY26 | −$0.19 | n/a | n/a | |
| Q2 FY25 | −$0.33 | n/a | −$1.23 | |
| Q1 FY25 | −$0.36 | n/a | −$1.24 | |
| Q4 FY24 | −$0.26 | n/a | −$1.30 | |
| Q3 FY24 | −$0.28 | n/a | −$1.49 | |
| Q2 FY24 | −$0.34 | n/a | −$1.67 | |
| Q1 FY24 | −$0.42 | n/a | −$1.80 | |
| Q4 FY23 | −$0.45 | n/a | −$1.88 | |
| Q3 FY23 | −$0.46 | n/a | −$2.07 | |
| Q2 FY23 | −$0.47 | n/a | −$2.24 | |
| Q1 FY23 | −$0.50 | n/a | −$2.40 |
Against its peers
Companies in Biotechnology nearest Iovance Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IOVAIovance Biotherapeutics | n/m | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| VCELVericel | $0.46 | +283% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| Peer median | $3.27 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Iovance Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.